Valachis, Antonis
Carlqvist, Peter
Ma, Yuanjun
Szilcz, Máté
Freilich, Jonatan
Vertuani, Simona http://orcid.org/0000-0002-9932-9476
Holm, Barbro
Lindman, Henrik http://orcid.org/0000-0002-5871-268X
Funding for this research was provided by:
Novartis Sweden was the sponsor of this study
Article History
Received: 18 October 2021
Revised: 29 April 2022
Accepted: 5 May 2022
First Online: 21 May 2022
Ethics approval and consent to participate
: The study was approved after vetting by the Regional Ethical Review Board in Stockholm, Sweden (2017/424).
: Not applicable.
: AV and HL have no competing interests. PC was an employee of Novartis Sverige AB at the time of the study and is currently a consultant at Nordic Market Access AB. MS was an employee of Parexel International at the time of the study, and is now in addition affilitated to Karolinska Institutet. YM and JF are employees of Parexel International who was commissioned by the sponsor to conduct this study. JF is now in addition affiliated to Umeå University. SV and BH are currently employees of Novartis Sverige AB, the sponsor of this study.